Penumbra, Inc. (PEN)

Market Cap	9.18B
Revenue (ttm)	1.28B
Net Income (ttm)	147.70M
Shares Out	39.00M
EPS (ttm)	3.74
PE Ratio	62.99
Forward PE	54.76
Dividend	n/a
Ex-Dividend Date	n/a

Volume	612,777
Open	246.34
Previous Close	247.99
Day's Range	232.51 - 247.77
52-Week Range	205.80 - 310.00
Beta	0.41
Analysts	Strong Buy
Price Target	307.50 (+30.57%)
Earnings Date	Nov 5, 2025

About PEN

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDW...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 18, 2015
• Employees: 4,500
• Stock Exchange: NYSE
• Ticker Symbol: PEN
• Website: https://www.penumbrainc.com

Financial Performance

In 2024, Penumbra's revenue was $1.19 billion, an increase of 12.86% compared to the previous year's $1.06 billion. Earnings were $14.01 million, a decrease of -84.59%.

Analyst Summary

According to 16 analysts, the average rating for PEN stock is "Strong Buy." The 12-month stock price target is $307.5, which is an increase of 30.57% from the latest price.

Price Target

$307.5

(30.57% upside)

Analyst Consensus: Strong Buy